[Chemoprevention of prostate cancer - a plea]. / Chemoprävention des Prostatakarzinoms - Ein Plädoyer.
Aktuelle Urol
; 43(3): 157-61, 2012 May.
Article
em De
| MEDLINE
| ID: mdl-22639024
ABSTRACT
The high disease prevalence, the presentation in older age, a frequently slowly progressing course of disease, and high costs make the diagnosis of and therapy for prostate cancer a special challenge for urologists. Effective prevention of the disease may help to improve some of the problems mentioned above. Two randomised, controlled studies have proved that effective chemoprevention of prostate cancer is viable using 5α-reductase inhibitors (finasteride, dutasteride). Furthermore, there is increasing evidence that other compounds, e. g., selective oestrogen receptor modulators (SERMs), NSAIDs and statins might also be effective. This review investigates potential risks and benefits of chemoprevention including a consideration of health economical aspects. The authors conclude that the options of chemoprevention should be investigated in an open and unbiased way.
Texto completo:
1
Temas:
ECOS
/
Aspectos_gerais
Bases de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
3-Oxo-5-alfa-Esteroide 4-Desidrogenase
/
Anti-Inflamatórios não Esteroides
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Moduladores Seletivos de Receptor Estrogênico
Tipo de estudo:
Clinical_trials
/
Risk_factors_studies
Limite:
Humans
/
Male
País/Região como assunto:
Europa
Idioma:
De
Revista:
Aktuelle Urol
Ano de publicação:
2012
Tipo de documento:
Article